Clinical Trials

Lung Neoplasms

NCT06675695 2026-01-30

Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases

Completed

4,864 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

674 enrolled 21 charts 1 FDA

EGFR-mutant Non-small Cell Lung Cancer

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

Phase 2 Active not recruiting

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03122717 2025-11-12

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1/2 Active not recruiting

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Lung Neoplasms

NCT00328562 2025-05-04

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

13 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

358 enrolled

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06592989 2025-01-10

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

Recruiting

20 enrolled

Adenoma, Islet Cell

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Lung Neoplasms

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

337 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00198380 2024-03-08

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

90 enrolled

Adenocarcinoma, Bronchiolo-Alveolar

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

452 enrolled 35 charts 1 FDA

46 enrolled

Head & Neck

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00483561 2023-09-13

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

26 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Phase 3 Terminated

41 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04642547 2023-08-01

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Phase NA Completed

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04179890 2023-05-25

UpSwinG

Completed

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

70 enrolled 11 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01570296 2023-03-29

BKM120

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03599518 2023-02-08

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

20 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02039674 2022-11-08

MK-3475-021

Phase 1/2 Completed

267 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

16 enrolled

Other solid neoplasm

Solid Tumor

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

66 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01951469 2022-03-08

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Phase 3 Unknown

160 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

300 enrolled

Tumor-Agnostic

Neoplasms

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02025218 2021-04-01

IRENE

Phase 2 Terminated

21 enrolled

Lung Neoplasms

NCT02893332 2021-02-03

Sindas

Phase 3 Terminated

200 enrolled

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Phase 1 Unknown

22 enrolled

NSCLC

NCT01556191 2021-01-08

LADIE

379 enrolled

Lung Neoplasms

NCT00052208 2020-10-30

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Phase 1/2 Completed

158 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04575415 2020-10-20

BELLA

Unknown

272 enrolled

NSCLC

NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Phase 2 Unknown

200 enrolled

Advanced NSCLC With EGFR Mutation

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02374645 2020-04-24

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

64 enrolled